manufacturers of glp 1 drugs GLP-1 Receptor Agonist Shortage: Challenges and Solutions in Type 2 Diabetes Care GLP-1 Costs Explained: Managing Coverage

You start with a 0.25 milligram dose for the first month then increase that to 0.50 milligrams

GLP-1 Receptor Agonist Market Key Players Novo Nordisk A/S (Ozempic, Wegovy, Rybelsus, Victoza, Saxenda) Eli Lilly and Company (Mounjaro, Zepbound, Trulicity) AstraZeneca PLC (Byetta, Bydureon BCise) Sanofi SA GlaxoSmithKline plc Pfizer Inc

Effective treatments, like GLP-1 drugs, are rarely risk-free

Improvements in access will take time, and require generation of compelling data (e.g., pharmacoeconomics, impact on comorbidities) and savvy commercial strategy

Ozempic and Wegovy, made by Novo Nordisk, mimic the effects of GLP-1, a type of hormone in the body that impacts everything from the brain to muscle to the pancreas, stomach and liver, according to the National Institutes of Health

28% point to a lack of supply of the drugs, an issue that has been widely reported